EU Yes For TiGenix Marks Tenth ATMP Approval in Ten Years
Executive Summary
TiGenix says its treatment for complex perianal fistulae in Crohn’s disease is the first allogeneic stem cell therapy to be approved under Europe’s centralized marketing authorization pathway.
You may also be interested in...
Stempeutics Eyes Global Markets For New Crohn's Symptom Cell Therapy
Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.
Takeda Secures TiGenix But Investor Shire Concerns Bubble Up
Takeda has closed its $630m acquisition of European regenerative medicine company TiGenix following a successful bid process, but is facing new pressure from a group of shareholders in Japan concerned about its planned purchase of Shire – valued at around 100 times that amount.
More New EU Drug Approvals Bring Total For Year To 14
Seven new drugs were approved in the EU in the March-April period this year: TiGenix/Takeda's Alofisel, BioCryst's Alpivab, Chiesi's Lamzede, AstraZeneca's Lokelma, Pfizer's Mylotarg, GSK's Shingrix and MSD's Steglatro.